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resumo 
 
 
O fungo patogénico Candida albicans tem a particularidade de possuir um 
tRNA (tRNACAG
Ser
) híbrido que é aminoacilado pelas sintetases SerRS e 
LeuRS. Esta característica é responsável pela ambiguidade do codão CUG 
que é decodificado como Ser (97%) e como Leu (3%). Estudos anteriores 
demonstraram que o nível de ambiguidade é variável dependendo da condição 
de crescimento do fungo e revelaram que estipes com maior erro de tradução 
crescem melhor na presença de azoís, particularmente em meio com 
fluconazol.   
Para analisar os efeitos dos erros de tradução na aquisição de resistência a 
drogas, construímos três estirpes de C. albicans (T0, T1 e T2) com níveis 
crescentes de incorporação de Leucina, inserindo uma cópia (T1) ou duas 
cópias (T2) do gene tDNACAG
Leu
. Estas estirpes foram evoluídas 
experimentalmente na presença e na ausência de fluconazol de acordo com o 
protocolo da EUCAST. O nível de ambiguidade destas estirpes foi avaliado 
durante o período da evolução usando um sistema reporter baseado na 
proteína fluorescente GFP. Finalmente foi também avaliada o tipo de 
resistência adquirida pelas estirpes ambíguas (resistência genética ou 
fenotípica).   
Os dados experimentais sugerem que a aquisição de resistência depende da 
droga e da percentagem do erro de tradução. As estirpes com maior erro de 
tradução (T2) adquirem mais resistência (256 µg/ml) e mais rapidamente 
sendo que mutações no gene ERG11 poderão ser responsáveis por essa 
resistência. Esta estirpe apresentou também um decréscimo da taxa de erro 
de tradução em ambas as evoluções (com e sem droga), resultado da deleção 
de uma das duas cópias do gene tDNACAG
Leu
. Este resultado reforça a 
instabilidade genética da estirpe T2.  
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abstract 
 
The human pathogen Candida albicans is characterized by the presence of a 
hybrid tRNA (tRNACAG
Ser
) that can be aminoacylated by both LeuRS and 
SerRS. This tRNA is responsible for the ambiguity of the CUG codon that can 
be decoded as serine (97%) and Leucine (3%). Previous studies showed that 
the level of ambiguity is variable depending on the growth condition of the 
fungus. These studies also revealed that strains mistranslating at a higher level 
grew better in the presence of azoles, particularly in the presence of 
fluconazole.  
To analyse the effect of translation errors on the acquisition of drug resistance, 
three strains of C. albicans were used (T0, T1 and T2). These strains have 
increasing levels of Leu misincorporation and were constructed by inserting a 
copy (T1) or two copies (T2) of a tDNACAG
Leu
 gene. These strains were evolved 
experimentally in the presence and absence of the antifungal agent according 
to the approved EUCAST protocol. The level of ambiguity of all strains was 
measured along the evolution experiment, using a reporter system based on 
the green fluorescent protein (GFP). Finally, the type of acquired resistance 
was also evaluated (genetic or phenotypic resistance).   
Experimental data suggest that the acquisition of resistance is dependent on 
the drug and the percentage of mistranslation. Strains with increased 
mistranslation (T2) acquired more resistance (256 µg/ml) and faster than the 
control T0.  Mutations in ERG11 gene might be responsible for this resistance. 
Also, T2 strain showed a decrease in the mistranslation level during both 
evolution experiments (with and without drug) as a consequence of the deletion 
of one of the two copies of the mutant tDNACAG
Leu
 gene. This result further 
highlights the genetic instability of strain T2.  
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I. Introduction 
 
1. Protein Synthesis – the Process of mRNA Translation 
 
All living systems store and transmit the genetic information to their offspring 
through the deoxyribonucleic acid (DNA). The functional parts of the DNA are 
called genes and they constitute the genome along with other elements. 
Transcription of this genetic information from DNA into messenger ribonucleic 
acid (mRNA) and its subsequent translation assures that the genome is used as 
the source of information for protein synthesis. This process in which the 
information in genes flows into proteins constitutes the Central Dogma of 
Molecular Biology, proposed by Crick (1). 
 
Decoding the genetic information contained in the mRNA into protein occurs in 
the ribosome, during the process of translation. This is achieved by pairing each 
amino acid-specific codon from the mRNA with a complementary sequence, the 
anticodon triplet of the transfer RNA (tRNA). The tRNA thus connects the 
worlds of nucleic acids and proteins, as it binds a specific amino acid 
corresponding to the anticodon. The enzymes that charge the tRNAs with the 
respective amino acids are the aminoacyl-tRNA synthetases (aaRSs) (2, 3).  
 
Translation can be divided into three steps: initiation, elongation and 
termination. In eukaryotes, the initiation step needs at least ten proteins, which 
are nominated eIFs (eukaryotic initiation factors). The proteins eIF-1, eIF-1A, 
and eIF-3 bind to the 40S ribosomal subunit, and eIF-2 (in a complex with GTP) 
associates with the initiator methionyl tRNA. The mRNA is recognized and 
transported to the ribosome via interactions with the eIF-4 group of factors. 
Another factor, eIF-4G, binds to both eIF-4E and to a poly-A binding protein 
(PABP) associated with the poly-A tail at the 3’ end of the mRNA. After, the 5’ 
and 3’ ends of mRNAs are recognized by eIFs. The initiation factors eIF-4E and 
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eIF-4G, in association with eIF-4A and eIF-4B, then bring the mRNA to the 40S 
ribosomal subunit, with eIF-4G interacting with eIF-3. The 40S ribosomal 
subunit is then bound to methionyl tRNA and eIFs, and this complex scans the 
mRNA until it recognizes the AUG initiation codon. After the AUG codon is 
reached, eIF-5 triggers the hydrolysis of GTP bound to eIF-2. Initiation factors 
are then released and the 80S initiation complex of eukaryotic cells is 
established, by junction of 60S and the 40S subunits (Figure 1) (4, 5).  
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Translation proceeds by elongation of the polypeptide chain. The mechanism of 
elongation in prokaryotic and eukaryotic cells is very similar. The ribosome has 
three sites for tRNA binding, designated the P (peptidyl), A (aminoacyl), and E 
(exit) sites. The initiator methionyl tRNA occupies the P site in the ribosome, 
and the A site is ready to receive an aminoacyl-tRNA by pairing with the second 
codon of the mRNA. The aminoacyl tRNA is followed to the ribosome by an 
elongation factor, eEF-1α in eukaryotes, which is in a complex with GTP. When 
the correct aminoacyl tRNA is inserted into the A site of the ribosome, the GTP 
is hydrolyzed to GDP, and the elongation factor bound to GDP is released 
(Figure 2). Next, a peptide bond is formed between the initiator methionyl tRNA 
at the P site and the second aminoacyl tRNA at the A site. This reaction is 
catalyzed by the large ribosomal subunit. The result is the transfer of 
methionine to the aminoacyl tRNA at the A site of the ribosome, forming a 
peptidyl tRNA at this position and leaving the uncharged initiator tRNA at the P 
site. The next step in elongation is translocation, which requires another 
elongation factor, eEF-2 in eukaryotes, and is again coupled to GTP hydrolysis. 
During translocation, the ribosome moves three nucleotides along the mRNA, 
positioning the next codon in an empty A site. This step translocates the 
peptidyl tRNA from the A site to the P site, and the uncharged tRNA from the P 
site to the E site. The ribosome is then left with a peptidyl tRNA bound at the P 
site, and an empty A site. The binding of a new aminoacyl tRNA to the A site 
then induces the release of the uncharged tRNA from the E site, leaving the 
ribosome ready for insertion of the next amino acid in the growing polypeptide 
chain (6). 
 
Figure 1 - Initiation of translation in eukaryotic cells. Initiation factors eIF-3, eIF-1, and eIF-1A bind to 
the 40S ribosomal subunit. The initiator methionyl tRNA is brought to the ribosome by eIF-2 (complexed to 
GTP), and the mRNA by eIF-4E (which binds to the 5´ cap), eIF-4G (which binds to both eIF-4E at the 5’ 
cap and PABP at the 3’ poly-A tail), eIF-4A, and eIF-4B. The ribosome then scans mRNA until recognize 
the AUG initiation codon. After that eIF-5 triggers the hydrolysis of GTP, followed by the release of the 
initiation factors. The 60S ribosomal subunit then joins the 40S complex (Adapted from reference 6). 
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The end of translation is signalled by the presence of one of three codons 
(UAA, UAG, or UGA) called stop codons at the A site. These are recognized by 
a release factor rather than by a tRNA. In eukaryotic cells the eRF-1 recognizes 
all three termination codons. The release factors bind to a termination codon at 
the A site and stimulate hydrolysis of the bond between the tRNA and the 
polypeptide chain at the P site, resulting in release of the completed polypeptide 
from the ribosome, followed by the dissociation of tRNA and mRNA from the 
ribosome. The ribosome separates into the large and small subunits, which can 
assemble on another mRNA molecule to begin a new round of protein synthesis 
(6).  
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1.1. mRNA Mistranslation – Error in Protein Synthesis 
 
The Central Dogma of Molecular Biology describes the ways in which 
information flows. First DNA replication (DNA to DNA), and then transcription 
(DNA to RNA), and finally translation (RNA to protein) (1) proceed with optimized 
levels of fidelity and speed. Of the three processes mRNA translation is more 
likely to experience errors and error rates are similar in eukaryotes and 
prokaryotes (7). The overall error rate of protein synthesis has been measured to 
be in the order of 10−3 – 10−4 (one error in every 1000 to 10000 codons 
translated) (8-10). 
 
Fidelity of translation mostly relies on the accuracy of tRNA aminoacylation and 
mRNA decoding by the ribosome. Mischarging of tRNAs may be caused by the 
failure of aaRSs to recognize their cognate tRNAs or by the activation of 
incorrectly bound amino acids. To minimize mischarging, some aaRSs have 
editing mechanisms that discard chemically similar amino acids from their active 
sites (11). The aaRSs use editing mechanisms that can occur before or after the 
transfer of the amino acids to the tRNA, namely pre-transfer editing (the 
hydrolysis of mischarged aminoacyl adenylates) or post-transfer editing (the 
hydrolysis of mischarged aminoacyl-tRNAs) , respectively (10). Pre-transfer 
editing can be either tRNA dependent or tRNA independent and occurs through 
a range of mechanisms that promote hydrolysis of the labile non-cognate (two 
Figure 2 - The elongation step in translation process. The ribosome has three tRNA-binding sites, 
designated P (peptidyl), A (aminoacyl), and E (exit). The initiating methionyl tRNA is positioned in the P 
site, leaving an empty A site. The second aminoacyl tRNA is then brought to the A site by EF-Tu 
(complexed with GTP). Following GTP hydrolysis, EF-Tu (complexed with GDP) leaves the ribosome, 
with second aminoacyl tRNA inserted into the A site. Forms a peptide bond, resulting in the transfer of 
methionine to the aminoacyl tRNA at the A site. The ribosome then moves three nucleotides along the 
mRNA and result in a translocation of  the peptidyl tRNA to the P site and the uncharged tRNA to the E 
site, leaving an empty A site ready for addition of the next amino acid. EF-Tu is the designations used for 
the bacterial elongation factors, in eucaryotes, is called EF-1 (Adapted from reference 6). 
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molecules matched not according to the rules of the genetic code) aminoacyl 
adenylate species, leading to the release of the non-cognate amino acid, AMP 
and PPi. In the post-transfer editing, the misacylated tRNA may be translocated 
from active site into the editing site of the aaRS, where the tRNA–amino acid 
ester linkage is hydrolyzed, releasing tRNA and amino acid. If the misacylated 
tRNA is released from the aaRS without being edited, it is subjected to 
hydrolysis by specific proteins named trans-editing factors. Finally, misacylated 
tRNAs can be discriminated by elongation factors (eEF-1A), which bind them 
too weakly for efficient delivery and release in the ribosome (12).  
 
Codon decoding errors are mainly caused by misreading of sense codons 
(missenseerrors) and nonsense codons (nonsense errors) by near cognate or 
noncognate tRNAs. The result is the synthesis of mutant proteins. Other causes 
for synthesis of mutant proteins are the loss of the reading frame 
(frameshifting), that alters the reading frame to the -1 or to the +1 frames by 
tRNA splippage during elongation, or by the premature ribosome drop off from 
the mRNA (processivity errors). Together, these errors result in premature 
translation termination and synthesis of truncated polypeptide (11, 13, 14). 
 
Although the presence of mutant proteins should be highly detrimental, 
organisms survive well with a protein synthesis error rate of 1 error in every 
1000 to 10000 codons translated. This suggests that apparently there is not an 
evolutionary pressure for the ribosome to be more accurate.  It is argued that 
this rate of fidelity represents a compromise between speed and accuracy that 
optimizes the fitness of the organism. In order to maintain cellular functionality 
eukaryotes use numerous quality control systems to deal with aberrant proteins, 
namely degradation by the ubiquitin-proteasome pathway, the chaperone 
mediated autophagy, or refolding by molecular chaperones (15). 
 
1.2. mRNA Mistranslation – Negative and Positive 
Features 
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Generally, the occurrence of mistranslation is considered deleterious and 
infrequent, but the observations of organisms that decode some codons 
ambiguously and the discovery of a compensatory increase in mistranslation 
frequency to combat environmental stress have changed the way that 
translational errors are viewed in decoding (16).  
 
In fact, some advantages of mistranslation are well described. For example, the 
non-methionyl tRNAs that can be methionylated by methionyl-tRNA synthetases 
from E. coli, yeast, and mammals, under conditions of oxidative stress. Because 
methionine may spontaneously react with reactive oxygen species (ROS) that 
are formed under oxidative stress, methionine residues mistranslated at non-
methionyl codons may contribute to decrease the presence of ROS, that are 
later reduced by methionine sulfoxide reductases (17).  
 
Another notable example is the CUG codon of C. albicans. This pathogen 
reassigned the CUG codon from leucine (Leu) to Serine (Ser) trough CUG 
decoding ambiguity, which resulted in proteomic and phenotypic diversity. Ser 
and Leu are incorporated in the C. albicans proteome with efficiencies of 97% 
and 3%, respectively, and it can tolerate up to 28% of Leu misincorporation 
without visible effects on growth rate (18, 19). The resulting proteomic and 
phenotypic diversity may make this opportunistic pathogen a ‘‘moving target’’ for 
the host’s adaptive immune system (20). 
 
In S. cerevisiae, ambiguity of the CUG codon does not generate the high 
phenotypic and morphological diversity observed in C. albicans, however it can 
increase the tolerance to many environmental agents and permits growth in the 
presence of lethal doses of cicloheximide, arsinite, cadmium, and salt (21).  
 
In another example, Mycoplasma spp. have error-prone LeuRS, PheRS and 
ThrRS with mutations and deletions in their editing domains (22). The 
mischarging of tRNAs by these AARSs increases mistranslation and leads to 
the production of statistical proteins with Phe/Tyr, Leu/Met and Leu/Val 
substitutions. The high frequency of mistranslation may provide a mechanism 
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for the remarkable phenotypic plasticity of Mycoplasma that in turn allow it to 
escape host defences (22). 
 
Recently, Javid and colleagues reported that mycobacteria substitute glutamate 
for glutamine and aspartate for asparagine at high rates under specific growth 
conditions. Increasing the substitution rate results in phenotypic resistance to 
rifampicin, whereas decreasing mistranslation produces increased susceptibility 
to the antibiotic (23). 
 
On the other hand, several mutations in aaRSs cause human neurological 
disorders, including the peripheral neuropathy CMT (Charcot–Marie–Tooth). 
Mutations in GARS, which encodes glycyl-tRNA synthetase, are linked to CMT 
disease type 2 because they affect the localization of glycyl-tRNA synthetase in 
granules within the cell bodies and neurite projections of neuronal cells, which 
results in a slowly progressive axonal polyneuropathy (24, 25). 
 
Another example of the negative effects of incorrect translation is described by 
Lee and collagues. The mouse sticky mutation affects the editing domain of 
alanyl-tRNA synthetase, leading to charging of tRNAAla with serine. The global 
misincorporation of serine at alanine codons results in the accumulation of 
intracellular misfolded proteins, protein aggregation and ubiquitination. 
Together, these phenomena lead to rapid loss of Purkinje cells and mouse 
premature death (25, 26). 
 
2. The Genetic Code 
 
The genetic code was first described by Crick in 1966 derived from studies in 
E.coli (27). It englobes a set of rules by which information encoded within mRNA 
is translated into proteins by living cells. It postulated that there are four 
ribonucleotide base combinations C (cytosine), G (guanine), A (adenine) and U 
(uracil), organized into nucleotide-triplets (codons), that must be employed to 
encode the 20 standard amino acids used by living cells to build proteins. The 
combinations of these bases in three different positions define 64 possible 
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codons, where 61 different codons are translated into 20 amino acids and 3 are 
stop codons (UAA, UAG and UGA codons). Therefore, it is clear that some 
amino acids are decoded by more than one codon, which makes the genetic 
code degenerate (Figure 3) (28, 29). These codons are named “synonymous 
codons”, except methionine (Met) and tryptophan (Trp), which are decoded by 
only one codon, AUG codon and UGG codon, respectively (30). One codon, 
AUG, has a double role because it specifies initiation of protein synthesis in 
addition to being a normal Met (methionine) codon (28). 
 
The emergence of two news amino acids, designated as the 21st and 22nd 
amino acids, nominated selenocysteine (Sec) (31)  and pyrrolysine (Pyl) (32) , 
respectively, confirms the expansion of the genetic code and its flexibility.  In 
this case, some organisms translate the UGA stop codon as Sec and UAG stop 
codon as Pyl (31, 32). 
 
The discovery that several organisms and organelles developed an alternative 
genetic code sets aside the hypothesis that the genetic code is frozen and 
universal. This also suggests that the evolution of alternative genetic codes may 
have physiological significance and may play an important role in the evolution 
of the species (21).  
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2.1. Natural Genetic Code Alterations 
 
After the discovery of codon reassignments in human mitochondrial genes  (33), 
a variety of other deviations from the standard genetic code in bacteria, 
archaea, eukaryotic nuclear genomes and, especially, organellar genomes have 
been reported (34). 
 
The mitochondrial genetic code seems to be particularly prone to change (with 
the exception of plants). For example, in the mitochondria of most organisms, 
the standard UGA stop codon codes for tryptophan, while the isoleucine-AUA 
codon codes for methionine (35). In the mitochondrial genomes of platyhelminths 
and echinoderms, the standard AAA-lys codon has been reassigned to 
asparagine (36). Among all mitochondrial reassignments, the arginine AGA/G 
codon pair is particularly interesting because it codes for different amino acids 
in different organisms. For example, AGA /G codes for termination in 
vertebrates, glycine in tunicates and serine in arthropods, echinoderms, 
molluscs, nematodes and platyhelminths (37). Also noteworthy is the 
mitochondrial genetic code of yeast in which UGA codes for tryptophan, AUA 
codes for methionine and not isoleucine, and the entire standard leucine-CUN 
codon family codes for threonine (38).  
 
In bacteria, genetic code changes have been found in Micrococcus, 
Mycoplasma and Spiroplasma (38). These genetic code changes involve 
reassignment of the UGA stop codon to tryptophan in Mycoplasma and 
Spiroplasma and the apparent non-assignment of the CGG arginine codon in 
Mycoplasma (38). In Micrococcus, the arginine AGA and the isoleucine AUA 
codons also appear to be unassigned (they do not appear to code for any 
amino acid) (38). 
Figure 3 - The standard genetic code. The codon series are shaded in accordance with the polar 
requirement scale values, which is a measure of an amino acid’s hydrophobicity: the greater 
hydrophobicity the darker the shading (the stop codons are shaded black) (Adapted from reference 29). 
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In eukaryotes, the UAG/A and UGA codons have been reassigned to glutamine 
and cysteine in ciliates, acetabularia and euplots, respectively (38), while the 
CUG codon has been reassigned to serine in some species of the genus 
Candida (39, 40).  
 
2.2. The Candida spp. genetic code 
 
A unique genetic code change is the reassignment of the CUG codon from 
leucine to serine in C. albicans and several other Candida species (41). This 
alteration to the standard genetic code is mediated through ambiguous codon 
decoding by a novel tRNA (figure 4), the Ser-tRNACAG, that is charged with both 
leucine (~3%) and serine (~97%) (42).  
 
This unique tRNA has identity elements for both the seryl-tRNA synthetase 
(SerRS) and the leucyl-tRNA synthetase (LeuRS), which allows the charging 
with both Ser and Leu. The SerRS recognizes the (GC)3 helix of the extra-loop 
and the discriminator base of the tRNA (G73) while the LeuRS recognizes A35 
and m1G37 in the anticodon-loop 
(43). Also, the novel ser-tRNA has a guanosine 
at position 33, a position that is almost always occupied by a pyrimidine or, 
more specifically, a uridine in all others serine tRNAs. U-33 is critical for the 
correct turn of the phosphate backbone and assembling of the anticodon bases 
(43). Despite this fact, studies have shown that G-33 has an important role in the 
reassignment mechanism because it lowers the decoding efficiency of the ser-
tRNACAG and minimizes mischarging of the ser-tRNACAG with leucine 
(34, 43, 44).  
 
rRNA and tRNA molecular phylogeny provides clear evidences that the Ser-
tRNACAG appeared approximately 272 ± 25 million years ago 
(45). The Ser-
tRNACAG was able to compete with the natural Leu-tRNACAG decoder for the 
CUG codon, thus generating an ambiguous CUG codon. This enabled CUG 
reassignment through selection of the mutant Ser-tRNA and elimination of the 
cognate Leu-tRNA. The Ser-tRNACAG was maintained in the lineage that 
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originated the genus Candida, but was lost in the lineage leading to the genus 
Saccharomyces. This separation occurred 170 million years ago, indicating that 
the yeast ancestor was ambiguous for at least 100 million years. CUG codon 
ambiguity imposed strong selection against old CUG codons, which mutated to 
UUG and UUA codons and this resulted in low CUG codon usage (45). Currently 
in the genus Candida, some species still have CUG ambiguity (as in the case of 
C. albicans), while others have achieved complete reassignment of the CUG 
codon (such as C. cylindracea) (46-48).  
 
2.3. Mistranslation in Candida albicans 
 
Under laboratory conditions, serine and leucine are incorporated into the C. 
albicans proteome with efficiencies of 97% and 3%, respectively, but such CUG 
ambiguity increases up to ~5% under stress (18). C. albicans tolerates up to 28% 
leucine misincorporation before mistranslation becomes noticeably detrimental 
Figure 4 - Secondary structure of the Candida albicans tRNACAG
Ser
. This unique tRNA has identity 
elements for both the seryl-tRNA synthetase (SerRS) and the leucyl-tRNA synthetase (LeuRS) and it is 
charged with both Ser  and Leu. The SerRS recognizes the (GC)3 helix of the extra-loop and the 
discriminator base of the tRNA (G73). The LeuRS recognizes A35 and m
1
G37 in the anticodon-loop. The 
G33 distorts the anticodon-arm of the tRNA and lowers the efficiency of leucylation of the tRNA 
(Adapted from reference 46). 
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to growth, suggesting that CUG ambiguity may fluctuate between 3% to 28%, 
depending on environmental conditions (18).  
 
Remarkably, CUG ambiguity increases secretion of lipases and proteases and 
cell adhesion and spawns a wide variety colony morphologies that reﬂect 
changes in the cell wall inﬂuencing fungal recognition by human immune cells 
(20, 49, 50). Recently, C. albicans recombinant strains were constructed by 
engineering Ser-tRNAs. This approach resulted in a series of strains 
mistranslating from 20% up to 99% of leucine at CUG positions. These highly 
ambiguous strains grew faster than the control in the presence of the oxidative 
stressors menadione and H2O2, in media supplemented with protein misfolding 
agents (urea and guanidine hydrochloride) and in media containing SDS and 
CuSO4 
(20). Also, the work from Bezerra and colleagues showed that strains with 
more leucine misincorporation grow faster than the control when they are in the 
presence of azoles, which is an indication of the fitness benefit that this 
alteration conveys (20). This result is of great importance because the ability of a 
pathogen with an altered genotype to survive in the presence and/or absence of 
drug greatly influences the degree to which that genotype will proliferate in the 
population and the degree to which it can be targeted if the drug regimen is 
changed (20, 50). 
 
Genome re-sequencing of the recombinant strains showed that increasing CUG 
ambiguity leads to rapid genome evolution through mutation and loss of 
heterozygosity (LOH) relative to the control strain of C. albicans. There was a 
near-complete LOH in a 300-kb region on chromosome V and the entire 
chromosome R in all strains with a level of leucine misincorporation higher than 
50%. Although some genes within this region have no known function, some of 
the known genes are involved in the regulation of biological processes, 
organelle organization, stress response, filamentous growth, pathogenesis, 
conjugation and antifungal drug resistance (20). In fact, LOH in the left arm of 
chromosome 5 is well described as a mechanism used by C. albicans to 
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increase resistance to fluconazole because it contains TAC1, the transcription 
factor that control expression of efflux pumps (51). 
 
In the part of the genome not affected by LOH, it was observed an increasing 
number of heterozygote SNPs for strains with increasing Ser-for-Leu 
misincorporation. For example, the ﬁlamentous growth regulators (FGRs) 
FGR23, FGR6-4, and FGR6-1 had more than three mutations, and members of 
the ALS family of cell surface glyco-proteins, namely ALS4 and ALS9, had two 
nonsynonymous mutations (20, 52). Since filamentation and adhesion are two of 
the most important aspects of the host-pathogen interaction, it is crucial to study 
the relevance of mistranslation to these features. 
 
3. Candida albicans biology 
 
3.1. Characteristics 
 
Candida albicans is a dimorphic fungus that exists as a commensal of warm-
blooded animals including humans. It colonizes mucosal surfaces of the oral 
and vaginal cavities and the digestive tract and is also able to cause a variety of 
infections, depending on the nature of the host defect (53). 
 
One of the most noteworthy features of this organism is its ability to grow with 
three distinct morphologies: the yeast, pseudohypha and hyphal forms. The 
unicellular yeast form is an ovoid-shaped budding yeast and the two distinct 
filamentous forms are elongated ellipsoid cells with constrictions at the septa 
(pseudohyphae) or parallel-walled true hyphae (Figure 5). C. albicans cells are 
also of two types, namely white and opaque cells, formed during switching and 
they may also form structures named chlamydospores, which are thick-walled 
spore-like structures (54, 55). 
 
This pathogen was first described in 1839 as a diploid organism with eight 
chromosomes. The size of the C. albicans genome is 13.3-13.4 Mb encoding 
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6,100-6,200 genes (48, 56, 57). For many years, it was thought that C. albicans 
was an obligate diploid (2N) but recently tetraploid and haploid cells have been 
detected (58, 59).  
 
To date, no complete sexual cycle has been observed in C. albicans. The 
described cycle for C. albicans is termed the parasexual cycle. In this case, 
mating of diploid cells is followed by mitosis and concerted chromosome loss 
instead of meiosis (60). Diploid cells (2n) of C. albicans are typically 
heterozygous at the mating type locus (MTL) but cells may lose their 
heterozygosity by loss of one copy of Chromosome 5, eliminating the a or α 
allele, to create α/α or a/a diploid strains (2n, opaque cells). When diploid a/a 
and α/α cells mate, they form tetraploid aa/αα cells (4n, white cells) which 
undergo mitosis and non-meiotic reduction in the number of chromosomes to 
return to diploid a/α cells (2n, white cells). The parasexual cycle is completed 
with no recognized meiosis (Figure 6) (60). Apparently, haploid cells also form via 
a non-meiotic reduction in chromosome number, similar to that seen in the 
tetraploid-to-diploid transition (58). The existence of semi-stable, non-diploid C. 
albicans cell types highlights the flexibility of the C. albicans genome (58). 
Furthermore, cases of aneuploidy (cells with an abnormal chromosome 
number) are especially common in fluconazole resistant strains (49).  
 
 
 
 
 
 
 
 
 
 
 
 
A              B                  C 
Figure 5 - Distinct morphologies of C. albicans, including yeast (A), pseudohyphae (B) and 
hyphae (C) (Adapted from reference 83). 
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3.2. Epidemiology 
 
C. albicans and a few other Candida species live in the oral cavity of up to 75% 
of the population. This colonization normally remains benign in healthy persons. 
However, individuals that are immunocompromised can often suffer from 
persistent infections of the oral cavity, denominated oral candidiasis (54). These 
are mostly caused by C. albicans and can affect the oropharynx and the 
esophagus of individuals with dysfunctions of the immune system. The major 
risk factors for developing oral candidiasis are HIV and the wearing of dentures 
and extremes of age (61).  
 
Studies estimated that approximately 75% of all women develop at least once in 
their lifetime vulvovaginal candidiasis, with 40–50% suffering at least one 
additional episode of infection. A small percentage of women (5–8%) suffer 
from at least four recurrent episodes per year. Predisposing factors for this type 
of infection are diabetes mellitus, the prolonged use of antibiotics, oral 
contraception, pregnancy and hormone therapy (61). 
 
Figure 6 - Parasexual cycle of C. albicans. Relatively to the MTL locus of C. albicans, diploid cells 
(2n) are a or α opaque cells, that mate efficiently to create tetraploid (4n) a/a/α/α cells. These cells can 
lose chromosomes to return to the diploid (2n) state (Adapted from reference 60). 
 
 
17 
 
Superficial C. albicans infections are non-lethal, but on the other hand, systemic 
candidiasis is associated with a high mortality rate, even with first line antifungal 
therapy. Risk factors leading to disseminated systemic candidiasis comprise 
neutropenia and damage of the gastrointestinal mucosa. Others risk factors 
include the use of central venous catheters, which allow direct access of the 
fungus to the bloodstream, the application of broad-spectrum antifungals, which 
enable fungal overgrowth, and gastrointestinal surgery, which disrupts mucosal 
barriers (54). 
 
3.3. Pathogenicity 
 
The notable capacity of C. albicans to infect diverse host niches is sustained by 
a wide range of virulence factors and fitness attributes. Among the most 
important are the morphological transition between yeast and hyphal forms, the 
expression of adhesins on the cell surface, thigmotropism, the formation of 
biofilms, phenotypic switching and the secretion of hydrolytic enzymes. 
Furthermore, fitness attributes include rapid adaptation to fluctuations in 
environmental pH, metabolic flexibility and strong stress response machineries 
(Figure 7) (54).  
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 7 - C. albicans pathogenic mechanisms. Cells adhere to the host cell surface by the expression 
of adhesins. Contact to host cells triggers the yeast-to-hypha transition and directed growth via 
thigmotropism. Adhesion, physical forces and secretion of fungal hydrolases facilitate the mechanism of 
invasion. Switching has been proposed to influence antigenicity and biofilm formation of C. albicans. 
(Adapted from reference 54).  
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3.3.1. Polymorphism 
 
Several environmental signals can affect the morphology of C. albicans cells. 
For example, at low pH (< 6) C. albicans cells predominantly grow in the yeast 
form, while at a high pH (> 7) hyphal growth is induced (62). In fact, a number of 
other conditions, including starvation, the presence of serum or N-
acetylglucosamine, temperature and levels of CO2 stimulate the formation of 
hyphae (63). 
 
Morphogenesis has also been shown to be regulated by quorum sensing, a 
mechanism used by C. albicans cells for communication. Due to quorum 
sensing, high cell densities (> 107 cells ml−1) produce farnesol that signals yeast 
growth, while low cell densities (< 107 cells ml−1) lead to hyphal formation (64). 
 
The transition between yeast and hyphal growth forms is termed dimorphism 
and it has been proposed that both growth forms are important for 
pathogenicity. The hyphal form has been shown to be more invasive than the 
yeast form, but the smaller yeast form is believed to represent the form primarily 
involved in dissemination (54, 65, 66).  
 
3.3.2. Adhesins 
 
C. albicans has a specialized set of proteins (adhesins) that mediate adherence 
to other C. albicans cells, to abiotic surfaces and to host cells (54). The best 
studied C. albicans adhesins are the agglutinin-like sequence (ALS) proteins. 
The ALS genes encode glycosylphosphatidylinositol (GPI)-linked cell surface 
glycoproteins and of the eight Als proteins, the hypha-associated adhesin Als3 
is required for viable hypha formation and it particularly important for adhesion 
(67). ALS3 gene expression is upregulated during infection of oral epithelial cells 
in vitro and during in vivo vaginal infection (68). Another important adhesin of C. 
albicans is Hwp1, which is localized on the cell surface as a hypha-associated 
GPI-linked protein (54). Interestingly, these ALS and HWP1 genes are rich in 
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CUG codons and misincorporation of leucine at these codons may strongly 
contribute to increased adhesion (50). 
 
Morphology-independent proteins can also contribute to adhesion. These 
include GPI-linked proteins such as Eap1, Iff4 and Ecm33, non-covalent wall-
associated proteins Mp65 (a putative β-glucanase) and Phr1 (a β-1,3 
glucanosyl transferase), cell-surface associated proteases (Sap9 and Sap10) 
and the integrin-like surface protein Int1 (69). 
 
3.3.3. Biofilm  
 
An additional important virulence factor of C. albicans is its capability to form 
biofilms on abiotic or biotic surfaces. Catheters, dentures (abiotic) and mucosal 
cell surfaces (biotic) are the most common substrates. Biofilms form in a 
chronological process including adherence of yeast cells to the substrate, 
followed by proliferation of these yeast cells and formation of hyphae in the 
upper part of the biofilm. Finally, there is accumulation of extracellular matrix 
material and dispersion of yeast cells from the biofilm complex (54). 
 
Several transcription factors control biofilm formation and these include Bcr1, 
Tec1 and Efg1 (70). For the dispersion phase in the C. albicans biofilm formation 
process, it was recently identified a key regulator, the major heat shock protein 
Hsp90, which is also required for antifungal drug resistance (71). 
 
3.3.4. Contact sensing and thismotropism 
 
An important environmental factor that triggers hypha and biofilm formation 
in C. albicans is contact sensing. After the contact with a surface, such as agar 
or mucosal surfaces, yeast cells switch to the hyphal form and can then invade 
into the substratum (72). Likewise, contact to different solid surfaces induces the 
formation of biofilms. For example, on surfaces with particular topologies (such 
as the presence of ridges) directional hyphal growth (thigmotropism) may occur 
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(54). Recently, studies demonstrated that thigmotropism of C. albicans hyphae is 
regulated by extracellular calcium uptake through the calcium channels Cch1, 
Mid1 and Fig1 (73). 
 
3.3.5. Secreted hydrolases 
 
Following the adhesion to host cell surfaces and hyphal growth, C. 
albicans cells can secrete hydrolases. These are thought to facilitate active 
penetration into the host cells (74). Also, secreted hydrolases are thought to 
increase the efficiency of acquisition of extracellular nutrients (75). Three different 
classes of secreted hydrolases are expressed by C.albicans: proteases, 
phospholipases and lipases (54). 
 
4. Antifungal drugs and resistance 
 
4.1. Mechanisms of action of antifungal drugs 
 
Treatment of Candida albicans infections is restricted to the classes and 
number of antifungal drugs available. The major classes of currently available 
antifungal drugs are the azoles, polyenes and echinocandins (Figure 9)  (76).  
 
The azoles affect the biosynthesis of ergosterol that constitutes the major sterol 
of the C. albicans plasma membrane. The azoles mechanism of action consists 
of inhibiting the enzyme sterol 14-α-demethylase (14DM), a cytochrome P-450 
enzyme (77) encoded by ERG11 gene. This is a key enzyme in the ergosterol 
biosynthesis pathway because it catalyzes the oxidative removal of the 14-α-
methyl group from lanosterol. Azoles enter the cell by facilitated diffusion and 
then bind to the heme group located in the active site of 14DM. The interference 
with the active site of the enzyme causes a block in the production of ergosterol 
and the accumulation of a toxic sterol produced by an enzyme encoded by 
ERG3 (78, 79). This toxic sterol exerts severe membrane stress on the cell, which 
can lead to its death (Figure 8A). 
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The triazole fluconazole is the most widely used drug to treat Candida infections 
because its target has no homologues with similar functions in humans (80). The 
downside of this drug is that it acts in a fungistatic rather than fungicidal 
manner. Consequently, there is not the complete eradication of the fungi in 
treatment of oropharyngeal candidiasis (80). Also, prolonged and repeated 
treatment of candidiasis with azoles has resulted in an increasing frequency of 
therapy failures caused by the development of fluconazole-resistant C. albicans 
strains (81). 
 
Unlike azoles, polyenes are fungicidal drugs with both hydrophobic and 
hydrophilic sides. They strongly bind to ergosterol in order to produce drug-lipid 
complexes, which insert into the fungal cell membrane to form a membrane-
spanning channel (82). This allows some ions, namely potassium, to leave the 
cell, which destroys the proton gradient (Figure 8B) (82).  
The polyene amphotericin B is effective against systemic fungal disease and 
has in vitro and in vivo activities against several Candida species as well as C. 
neoformans and Aspergillus species (83). The main limitation of their use is host 
toxicity, probably as a consequence of the structural similarities between 
ergosterol and cholesterol in the mammalian cell membrane (83, 84). 
 
The most recent drugs to be used are the echinocandins caspofungin, 
micafungin and anidulafungin. The echinocandins are large lipopeptides that act 
as non-competitive inhibitors of the (1,3)-β-D-glucan synthase, an enzyme 
involved in fungal cell wall synthesis (85). The inhibition of this enzyme results in 
the loss of cell wall integrity, which causes severe cell wall stress on the fungal 
cell (Figure 8C). The activity of the echinocandins is generally fungicidal against 
yeast but fungistatic against fungus. For example, it has been reported a 
notable antifungal activity against Candida and Aspergillus but the 
echinocandins show no antifungal activity against C. neoformans (83, 84). 
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Figure 8 - Mechanisms of action of antifungical drugs. (A) The azoles function by targeting the 
ergosterol biosynthetic enzyme lanosterol demethylase, encoded by ERG11, causing the accumulation of a 
toxic sterol. (B) The polyenes are amphipathic drugs that function by binding to ergosterol to create drug-
lipid complexes, to form a membrane-spanning channel, causing an osmotic cellular lysis. (C) The 
echinocandins act as noncompetitive inhibitors of (1,3)-β-D-glucan synthase, encoded by FKS1, causing a 
loss of cell wall integrity. (Adapted from reference 83) 
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4.2. Mechanisms of drug resistance 
 
C. albicans can exploit several cellular stress responses to tolerate exposure to 
the azoles and can also acquire high levels of resistance by multiple distinct 
mechanisms. These mechanisms are based in the alteration of the target 
enzyme, up-regulation of multidrug transporters and cellular stress responses 
(Figure 9) (20, 83, 84, 86). 
 
The alteration of the target enzyme, Erg11, is one mechanism of triazole 
resistance. At least 12 mutations in Erg11 have been associated with triazole 
resistance because the majority of these mutations alter the target, which 
hinders binding of the azole to its target (87-89). Upregulation of ERG11 has also 
been associated with azole resistance (90). An intriguing mechanism involving 
genomic alterations that amplify the copy number of ERG11 was recently 
identified in azole-resistant strains (91, 92). These alterations include mitotic 
recombination, gene conversion, and the formation of isochromosome 5 that 
confer resistance by increasing the gene dosage of ERG11 and the gene 
encoding the transcription factor Tac1 that regulates the expression of multidrug 
transporters (51, 91, 92). 
The second mechanism of azole resistance is the upregulation of multidrug 
transporters. For example, constitutive upregulation of Mdr1, which is a 
transporter that belongs to the major facilitator superfamily, confers resistance 
to fluconazole (93). Several studies also discovered the identity of the key 
transcription factor regulating the multidrug transporter (MRR1). They also 
revealed the associated mutations causing hyper-activation of this transcription 
factor leading to constitutive MDR1 overexpression (94). Constitutive 
upregulation of the members of the ATP-binding cassette (ABC) transporter 
superfamily CDR1 and CDR2 is the most-frequently encountered azole 
resistance mechanism in clinical isolates (93). Multiple regulatory elements have 
been identified along with the key transcription factor regulating the expression 
of these transporters, TAC1 (95, 96).  
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In addition to the two mechanisms that minimize the impact of the drug on the 
cell, other mechanisms are related to cellular stress responses (84). One well-
characterized mechanism that falls into this category involves the loss of 
function of Erg3 in the ergosterol biosynthetic pathway. This blocks the 
accumulation of the toxic sterol intermediates when Erg11 is inhibited by the 
azoles (78, 79). Some resistance mechanisms have a dual role by minimizing the 
impact of the drug on the cell and enabling the cell to cope with stress. For 
example, the transcription factors MRR1 and TAC1 regulate targets in addition 
to the efflux pumps mentioned above. MRR1 regulates oxidoreductases, which 
may help prevent drug-induced cell damage resulting from the generation of 
toxic molecules (97). TAC1 also regulates a glutathione peroxidase, a 
sphingosine kinase and a phospholipid flippase, which have important roles in 
oxidative stress response and lipid metabolism (96).  
 
Calcineurin is part of another pathway mediating crucial responses to antifungal 
drugs (98, 99). This molecule mediates essential responses to diverse stresses, 
including exposure to serum (100), alkaline pH (101) and agents inducing cell 
membrane stress (102). One downstream effector of calcineurin is the 
transcription factor Crz1 that has been associated with azole resistance in C. 
albicans by several recent studies (103). Crz1 is dephosphorylated by calcineurin. 
Once it is dephosphorylated, Crz1 translocates to the nucleus where it activates 
the expression of a set of genes involved in signalling pathways, ion/small-
molecule transport, vesicular trafficking and particularly cell wall integrity (104).   
 
Another regulator of cellular signalling that plays a key role in azole resistance 
is the molecular chaperone Hsp90 (105, 106). Hsp90 interacts with the catalytic 
subunit of calcineurin and it is required for its function (107). In fact, inhibition of 
Hsp90 with the metabolites geldanamycin and radicicol (they bind to the ATP 
binding pocket of Hsp90 (108)) prevents the rapid emergence of drug resistance 
in C. albicans in a laboratory experiment (109). Hsp90 inhibitors also reduce the 
resistance of Erg3 loss-of-function mutants and clinical isolates that have 
acquired resistance by multiple mechanisms (109, 110).  
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The stress responses that mediate azole resistance also include the conserved 
cyclic AMP (cAMP)-protein kinase A (PKA) signaling pathway (111, 112). The 
production of cAMP is regulated by adenylate cyclase and cyclase-associated 
proteins and the deletion of these proteins in C. albicans confers 
hypersensitivity to azoles that is in part reversed by the addition of cAMP to the 
medium (113).  
 
Finally, an interesting way in which signalling pathways can mediate azole 
resistance is the formation of fungal biofilms (114, 115). The mechanisms of azole 
resistance in C. albicans biofilms are probably multifactorial, including 
upregulation of multidrug transporters, reduced drug diffusion, reduced growth 
rate and alterations of the plasma membrane and cell wall (114). It is now clear 
that multiple signalling pathways are a prerequisite to sense environmental cues 
and activate cascades of events that eventually leads to biofilm-mediated azole 
resistance (84). 
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Relatively to polyenes, the main problem is the severe host toxicity rather than 
drug resistance (116). Cases of resistance to amphotericin B have been reported 
in C. albicans but the majority of amphotericin B resistance is related with 
reduced ergosterol content in the cell membrane. In most cases this is caused 
by defective Erg3 function (Figure 10) (117). Resistance to polyenes was also 
observed for patients previously treated with azoles because long-term 
fluconazole therapy causes defects in the C-5,6-desaturase, which blocks the 
synthesis of ergosterol and leads to the accumulation of an alternate sterol in 
the membrane (118). 
 
The relation between amphotericin B resistance and cellular signaling is poorly 
understood. This may be related to the fact that amphotericin B is fungicidal 
against Candida species and causes leakage of cytoplasmic contents (119). Until 
now, both key regulators of stress responses, Hsp90 and calcineurin, have not 
been directly implicated in resistance to amphotericin B (120). 
Similar to what happens to the azoles, C. albicans biofilms show resistance to 
treatment with polyenes and this has been attributed to the presence of 
persister cells within the population (121). 
 
 
 
 
 
 
 
Figure 10 – Mechanism of resistance to polyenes. Reduced ergosterol content due to the mutations in in 
Erg3 leading to the accumulation of an alternated sterol in membrane (Adapted from reference 83). 
 
Figure 9 - C.albicans azole resistance mechanisms.  (A) Mutation or upregulation of the target of thehe 
azoles, cytochrome P45014DM (also known as lanosterol 14α-demethylase). (B) Constitutive upregulation of 
members of the ABC transporter family of multidrug efflux pumps and upregulation of a major facilitator 
transporter. (C) Loss-of-function mutation of Erg3. (D) The molecular chaperone Hsp90 stabilizes 
calcineurin, thereby enabling calcineurin-dependent stress responses that are required for triazole tolerance. 
Multiple downstream effectors of calcineurin mediate cellular responses to azoles, including the 
transcription factor Crz1 (Adapted from reference 84). 
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The clinical use of echinocandins is fairly recent, but cases of resistance to this 
treatment have also been reported (122). The target of the echinocandins is the 
(1,3)-β-d-glucan synthase, that is a complex enzyme composed of two subunits, 
Fks1 and Rho1 (Figure 11). The catalytic subunit is encoded by FKS1 and the 
regulatory subunit is encoded by RHO1 (123, 124). Usually, this type of resistance 
is mediated by mutations in the FSK1 gene, particularly in two regions, the 
Hotspot 1 (HS1) and Hotspot 2 (HS2). The region around Ser645 (within HS1) 
is considered to be the major contributor for echinocandins resistance (125, 126).  
 
Unlike the azoles, multidrug efflux transporters play a small role in echinocandin 
resistance. Studies showed that the overexpression of the ABC transporter 
Cdr2 confers a moderate increase in caspofungin resistance (127).  
 
On the other hand, there is a relation between cellular stress responses and the 
ability to survive to the stress employed by the echinocandins. The inhibition of 
the synthesis of (1,3)-β-d-glucan by echinocandins causes loss of cell wall 
integrity and induces severe cell wall stress (126). Rho1, that is a positive 
regulator of (1,3)-β-d-glucan synthase, also coordinates the protein kinase C 
(PKC) cell wall integrity signaling pathway that is responsible for remodeling the 
cell wall (128, 129). Recent works also demonstrate the involvement of calcineurin 
signaling in echinocandin resistance. The calcineurin-dependent transcription 
factor Crz1 is required for activation of the expression of several chitin 
synthases in response to stress conditions (97). The upregulation of this enzyme 
elevates chitin content in the cell wall and make cells less susceptible (130).  
 
The biofilm cellular state does not seem to confer resistance to echinocandins 
(114). When C. albicans cells grow under high concentration of echinocandins, 
the clinical isolates grow better compared with planktonic counterparts. This can 
be related to increased (1,3)-β-d-glucan content in C. albicans cell walls from 
biofilms compared to the (1,3)-β-d-glucan content in planktonic cells (131).  
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5. Objectives 
 
Pathogenic yeasts from the genus Candida can cause serious infections in 
humans, particularly in immunocompromised patients. In recent years, 
resistance to frequently administered antifungal drugs is increasing (132).  
 
Phenotypic variability and genomic plasticity are considered driving forces 
during evolution of drug resistance (133) and considering the high phenotypically 
diversity in ambiguous C. albicans strains we asked if tRNA mistranslation in 
this pathogen favours adaptation under antifungal drug treatment. Fluconazole 
was chosen for this project because it is the most widely used antifungal in 
clinics nowadays. The specific objectives addressed in this thesis were the 
following: 
 
Figure 11 – C. albicans echonocandin resistance. Mutations in the (1,3)-β-d-glucan synthase subunit 
encoded by FSK1 confers resistance by minimizing the impact of the drug on the cell (A). Rho1 is a positive 
regulator of glucan synthase and contributes to tolerance through stress responses (B) (Adapted from 
reference 84). 
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1. Analyze the effect of mistranslation on the acquisition of resistance to 
fluconazole.  
 
2. Measure mistranslation levels during long-term evolution of drug 
resistance. 
 
3. Identify molecular determinants by which resistance evolves in 
mistranslating strains. 
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II. Material and Methods 
 
1. Strains and growth conditions 
 
Candida albicans SN148 (arg4∆/arg4∆ leu2∆/leu2∆ his1∆/his1∆ 
ura3∆::imm434/ura3∆::imm434iro1∆::imm434/iro1∆::imm434) (134) was grown at 
30°C in YPD (2% glucose; 1% yeast extract, and 1% peptone). C. albicans 
strains T0, T1 and T2 were grown in minimal medium lacking uridine (0.67% 
yeast nitrogen base without amino acids, 2% glucose, 2% agar and 100 μg/ml 
of the required amino acids). Cells were grown aerobically at 30°C unless 
indicated otherwise.  All C. albicans strains used in this study are listed in Table 
1 below. 
 
Table 1- C. albicans strains used in this study. 
 
    Strains Genotype % mistranslation 
T0 
arg4∆/arg4∆ leu2∆/leu2∆ his1∆/his1∆ 
ura3∆::imm434/ura3∆::imm434 
iro1∆::imm434/iro1∆::imm434 RPS1/rps1∆::pUA709 
(URA3) 
1.45 
T1 
arg4∆/arg4∆ leu2∆/leu2∆ his1∆/his1∆ 
ura3∆::imm434/ura3∆::imm434 
iro1∆::imm434/iro1∆::imm434 RPS1/rps1∆::pUA702 
(URA3, Sc tLCAG) 
20.61 
T2 
arg4∆/arg4∆ leu2∆/leu2∆ his1∆/his1∆ 
ura3∆::imm434/ura3∆::imm434 
iro1∆::imm434/iro1∆::imm434 RPS1/rps1∆::pUA706 
(URA3, Sc tLCAG, Sc tLCAG) 
67.29 
 
 
2. Experimental evolution with fluconazole 
 
9 clones of each of the ambiguous strains T0, T1 and T2 were inoculated in 
RPMI 1x media (Sigma) in a 96-well format plate and incubated at 37ºC (Figure 
12). An aliquot of stationary phase cultures was transferred to fresh media 
every 2 days using a multichannel pipette. Each passage the fluconazole 
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(Sigma Aldrich) concentration of the liquid growth medium was adjusted to a 
concentration corresponding to twice the last measured MIC (minimum 
inhibitory concentration). Passages were pursued until clones were growing in 
liquid media containing a fluconazole concentration of 256 µg/ml. The same 
experimental evolution approach was used for approximately 200 generations in 
liquid media without the drug. In both situations, all clones from each passage 
were frozen with 40% glycerol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Determination of broth dilution MICs 
 
Resistance to antifungal drugs was monitored at each passage using the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST protocol) 
(135) with alterations, as described below. A 96-well plate was prepared with a 
broth dilution series of fluconazole (0.125 – 256 µg/ml range) and control wells 
without drug (Figure 13). The plate was inoculated with a standardised number 
of cells from each clone of each strain (2,5x104 cells counted using the TC10tm 
Figure 12 - 96-well plate used in evolution with fluconazole. The A correspond to the T0 strain, the D 
correspond to T1 strain and G correspond to the T2 strain. The 1, 2, 3, 5, 6, 7, 9, 10, 11 spots correspond to 
the nine different clones of each strain that were growing in liquid media containing fluconazole at twice the 
last measured MIC. The A4, A8, A12, D4, D8, D12, G4, G8, G12 correspond to controls spots containing 
only RMPI media. 
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Automated cell Counter from BioRad). The microdilution plate was incubated 
without agitation at 37ºC for 24 ± 2 h. After this period the absorbance of the 
plate at 600 nm was recorded using the iMARKtm Microplate Reader. Failure to 
reach an absorbance of 0.2 after 48 h constituted a failed test. The value of the 
MIC for each passage was the lowest fluconazole concentration giving rise to 
an inhibition of growth of ±50% of that of the drug free control. 
  
 
 
 
 
 
 
 
 
 
 
 
 
4. Quantification of leucine misincorporation 
 
The levels of mistranslation during the evolution were assessed using a reporter 
system based on the yeast enhanced fluorescent protein (yEGFP). This protein 
permits quantification of mistranslation by fluorescence microscopy using a 
method described by Bezerra and colleagues (20). The reporter is based on a 
“gain of function” mutation at the yEGFP gene. The reporter has no activity 
when faithfully translated but if the reporter is expressed in cells mistranslating 
the mutated codon, a small portion of the reporter molecules are functional. The 
Figure 13 - 96-well plate used to determine broth MICs. The 1, 2, 3 spots were inoculated with one clone 
of the T0 strain; 5, 6, 7 with one clone of the T1 strain and  9, 10, 11 with to one clone of the T2 strain. The 
4, 8, 12 spots correspond to controls containing media without drug. A, B, C, D, E, F, G, H correspond to 
different and crescent fluconazole.concentrations. 
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degree of activity detected (fluorescence) when compared to the wild-type 
functional protein allows the quantification of the mistranslation rate. 
 
yEGFP expression was visualized in C. albicans cells at the beginning, middle 
and final points of the experimental evolution. Clones were grown overnight in 
liquid medium at an OD600 of 2.0-2.5 and aliquots were spotted onto microscope 
slides. Fluorescence was detected using a Zeiss MC80 Axioplan 2 light 
microscope, equipped for epifuorescence microscopy with the filter set HE38. 
Photographs were taken using an AxioCam HRc camera and images were 
analysed using ImageJ software. Mean fluorescence intensities (± standard 
deviation) were quantified in individual C. albicans cells containing the reporter 
yEGFP Leu-UUA201 (positive control), Ser-UCU201 (negative control) and 
Ser/Leu-CUG201 (reporter). yEGFP fluorescence (intensity/pixel) was 
determined for at least 1000 cells in each case. 
 
5. DNA extraction 
 
The DNA extraction was performed for each clone of all strains. Genomic DNA 
extraction was carried out using an adaptation of the protocol described by 
Hoffman (136). 1mL of culture (OD600nm between 0.5 and 1.0) was harvested by 
centrifugation. After centrifugation, cells were resuspended in 0.1 ml of Solution 
I (1M sorbitol, 0.1M Na2EDTA, pH±7.5). 5 µl of a 10 mg/ml solution of lyticase 
100T was added and the suspension was incubated for 1 hour at 37ºC. 
 After incubation, the mixture was centrifuged in a microfuge for 1 minute a 
10 000 rpm. The supernatant was discarded and cells were resuspended in 0.1 
ml of solution II (50 mM Tris-Cl (pH±7.4), 20 mM Na2EDTA). After, 0.001 ml of 
10% SDS was added and stirred well. The mixture was incubated for 30 
minutes at 65ºC. 0.004 ml of 5M potassium acetate was added and the 
microfuge tube was placed in ice for 1 hour. After the incubation, the 
suspension was centrifuged in a microfuge for 5 minutes. The supernatant was 
transferred to a fresh microfuge tube and2V of 100% ethanol kept at -30ºC was 
added along with 0.1V of 5M NaCl. The mixture was precipitated for 2 hours at -
 
34 
 
30ºC. After precipitation, the mixture was centrifuged in microfuge for 10 
minutes. The supernatant was pour off and the pellet air-dried. The pellet was 
then ressuspended in 0.3 ml of H2O miliQ and the sample was stored at -30ºC. 
 
6. PCR 
 
Amplification of the RPS10 locus fragment from each clone was performed 
according to current polymerase chain reaction protocols. In an eppendorf, 1 µl 
of DNA sample (± 100ng/ml) was added to 14 µl of the PCR mix. The mix for 
each reaction was composed of 1.5 µl Dream Taq Buffer 10x, 0.3 µl 10mM 
dNTP's, 0.3 µl of 10 mM oUA2058 primer, 0.3 µl of 10 mM primer oUA1554, 
0.075 µl of Dream Taq 5U / µl and 11.525 µl of H2O miliQ. 
 
Amplification of ERG11 from each clone was performed according to current 
polymerase chain reaction protocols. In an eppendorf, 1 µl of DNA sample (± 
100ng/ml) was added to 14 µl of the PCR mix. The mix for each reaction was 
composed of 1.5 µl Dream Taq Buffer 10x, 0.3 µl 10mM dNTP's, 0.3 µl of 10 
mM OUA2060 primer, 0.3 µl of 10 mM primer OUA2061, 10 mM OUA2062 
primer, 10 mM OUA2063 primer, 10 mM OUA2064 primer, 10 mM OUA2065 
primer, 0.075 µl of Dream Taq 5U / µl and 11.525 µl of H2O miliQ. All primers 
used are listed in Table 2 below. 
PCRs were performed in the My CiclerTM thermal-cycler (BIO RAD). An initial 
step of denaturation has lasted 3 minutes at 95 ° C. The heat-denaturation step 
has lasted 30 seconds at 95ºC, the annealing step has lasted 30 seconds at 
59ºC, and the extension step has lasted 1 minute at 72°C. The second, third 
and fourth steps were performed for 30-35 cycles. The last step was one cycle 
of 5 minute at 72ºC. The PCR product was subjected to a gel electrophoresis 
for quality check. 
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Table 2 - Sequence of primmers used. 
Primmer Sequence 
OUA1554 5'-CGTATTCACTTAATCCCACAC-3' 
OUA2058 3’-CGGATAACAATTTCACACA-5’ 
OUA2060 5’-GACAAAGAAAGGGAATTCAATC-3’ 
OUA2061 3’-CCAAATAAAGATCTTGAAGCAG-5’ 
OUA2062 5’-TGCCAATGTTATGAAAACTC-3’ 
OUA2063 3’-GAGAAACTAAAACATAATGAC-5’ 
OUA2064 5’-ATCAACCGATTCCGCCTCAC-3’ 
OUA2065 3’-ATCAACCGATTCCGCCTCAC-5’ 
 
 
7. Purification of DNA 
 
After DNA extraction and amplification, the RPS10 fragment was purified using 
the Qiagen PCR Purification Kit. 5 volumes of Buffer PB and 10 µl sodium 
acetate were added to each sample. The mixture was then passed through a 
column of the kit and centrifuged up to 1 minute at maximum speed. The 
column was washed with 750 µl of Buffer PE, and centrifuged up to 1 minute at 
maximum speed. The column was centrifuged once again to remove residues. 
The column was placed in an eppendorf and 35 µl of H2O milliQ was added, 
and the column was centrifuged for 1 minute at maximum speed. The remaining 
DNA was quantified using the NanoDrop equipment.  
 
Approximately 2µg of DNA was sent to StabVida for sequencing using the 
Sanger method. 
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III. Results  
 
1. Analyze the effect of mistranslation on the acquisition of 
resistance to fluconazole. 
 
Candida albicans is one of the leading causes of hospital-acquired bloodstream 
infections (137, 138). Resistance to frequently administered antifungal drugs is 
increasing, particularly fluconazole that is the most widely used antifungal in 
clinics nowadays (49). These facts highlight the importance of understanding the 
mechanisms behind the acquisition of resistance (83). 
Candida pathogens are unique in their natural ability to mistranslate at high 
level. The CUG codon is decoded as both leucine (3%) and serine (97%) due to 
a single tRNA species (tRNACAG
Ser) that is the substrate for two tRNA 
synthetases, namely the seryl and leucyl-tRNA synthetases (42, 44). Exposure of 
C. albicans to oxidative, pH stress and antifungals increases Leu 
misincorporation levels from 3% to 15%, suggesting that mistranslation may be 
part of the pathogen response to immune cells and antifungals (18). The ability of 
this pathogen to tolerate high levels of mistranslation was further demonstrated 
when Bezerra and colleagues constructed a series of recombinant strains that 
were able to incorporate from 20% up to 99% of leucine at CUG positions (20). 
These strains were constructed by engineering Ser-tRNAs that were able to 
decode the CUG codon and expressing them in C. albicans SN148 strain. This 
manipulation revealed that the high misincorporating strains, namely T2 with 
67% of ambiguity at CUGs, displayed remarkable phenotypic diversity, highly 
variable colony and cell morphologies and increased tolerance to antifungals 
(20). 
 
These results raised the question of whether tRNA mistranslation could favour 
adaptation and subsequent acquisition of resistance under antifungal drug 
treatment. Therefore, in order to analyze the effect of mistranslation on the 
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acquisition of fluconazole resistance, we measured adaptation to inhibitory 
concentrations of the drug in replicated experimental populations founded from 
three drug-sensitive strains of C. albicans and reared over approximately 200 
generations. We took advantage of the mistranslating strains constructed by 
Bezerra and colleagues, specifically strains T0, T1 and T2 that are 
characterized by different levels of leucine misincorporation at serine CUGs: 
1.5%, 20% and 67%, respectively (20). The experimental evolution protocol that 
we used to investigate the emergence of drug resistance in C. albicans was 
similar to that used in studies of adaptation in large populations of bacteria (139, 
140) and other fungi (141). 
 
Nine clones of each of the strains T0, T1 and T2 were grown in liquid media 
with fluconazole, and nine other clones were propagated without drug. Clones 
were inoculated in RPMI media in a 96-well format plate. Each passage, the 
fluconazole concentration of the liquid growth medium was adjusted to a 
concentration corresponding to twice the last measured MIC. Passages were 
pursued until clones were growing in liquid media containing a fluconazole 
concentration of 256 µg/ml. Resistance to antifungal drugs was monitored at 
each passage using the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST protocol) (135). The value of the MIC for each passage was 
the lowest fluconazole concentration giving rise to an inhibition of growth of 
±50% compared to the growth in the drug free control.  
 
Results showed that in the absence of fluconazole, every clone of each strain 
(T0, T1 and T2) preserved the sensitivity levels throughout evolution (MIC~ 
0.125 µg/ml) (Figure 14). This result suggests that mistranslation by itself 
(without the pressure factor of the presence of the drug) does not lead to 
acquisition of resistance to fluconazole.  
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The results of the experimental evolution with fluconazole showed that among 
the 9 clones of strain T0, two clones (UCU2 and UUA2) achieved the highest 
level of fluconazole resistance (MIC~256 µg/ml) and retained this level to 
generation 200 (Figure 16A). One population (UCU1) achieved an intermediate 
level of resistance (MIC~ 32 µg/ml) and then showed a decrease (MIC~ 4 
µg/ml). The remaining evolved populations kept their MIC at levels between 0.5 
µg/ml and 8 µg/ml (Figure 15A). 
 
Among the 9 clones of the strain T1, two clones achieved the highest level of 
fluconazole resistance (MIC~ 256 µg/ml) but one of the clones did not maintain 
the resistance. In the following passage, it immediately decreased its MIC to 
120 µg/ml (Figure 16B). Clone UUA1 obtained a final MIC of 32 µg/ml but the 
majority of the evolved populations achieved a MIC of 16 µg/ml and retained 
this level until generation 200 (Figure 15B).  
 
Finally, among the 9 clones of strain T2, five clones achieved the highest level 
of fluconazole resistance (MIC~ 256µg/ml) and all of them retained this level 
until generation 200 (Figure 15C). One population (UCU1) achieved an 
intermediate level of resistance (MIC~ 32 µg/ml) and then showed a decrease 
(MIC~ 2 µg/ml). The remaining evolved populations kept their MIC at 2 µg/ml 
(Figure 15C). 
 
Thus, strains with more ambiguity, T1 and T2, obtained higher levels of 
resistance in relation to T0 strain. Moreover, the T2 strain acquired more 
resistance, quicker and more stable compared to clones of the strains T0 and 
T1 (Figure 15).  Also, it is noteworthy that in passage 5 occurred the breakpoint 
Figure 14 - Experimental evolution of 9 clones of each strain T0, T1 and T2 without 
fluconazole. Cultures were grown at 37ºC in RPMI media. The MIC values were determined 
using the European Committee on Antimicrobial Susceptibility Testing (EUCAST protocol) and 
revealed the lowest fluconazole concentration giving rise to an inhibition of growth of ±50%. The 
MIC values for strains T0 (A), T1 (B) and T2 (C) are the same during the 10 passages 
(MIC~0.125µg/ml). 
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for the three strains (T0, T1 and T2). After that, there was a noticeable increase 
of resistance in each of the strains tested. 
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2. Measure mistranslation levels during long-term evolution of 
drug resistance. 
 
To verify if throughout the experimental evolution there were changes in the 
ambiguity levels of the strains (T0, T1 and T2), we used a reporter system 
based on the yeast enhanced fluorescent protein (yEGFP). This reporter was 
first described in Bezerra et al. (20) and allows the quantification of mistranslation 
through fluorescence microscopy. 
 
The reporter is based on a “gain of function” mutation at the yEGFP gene. 
Typically, there is a UUA-Leu codon at position 201of this gene and the cognate 
tRNALeu inserts leucine. The leucine insertion at this critical position actives GFP 
and there is the release of fluorescence. When this codon was mutated to a 
UCU-Ser codon at position 201, the corresponding cognate tRNA inserted 
serine. The incorporation of serine inactived GFP and no release of 
fluorescence was observed. In this situation, the residual fluorescence is the 
auto-fluorescence of the cell. Finally, when the 201 position was mutated to the 
ambiguous CUG codon, there could be decoding by the endogenous 
tRNASerCAG and the mutant tRNA
Leu
CAG. Consequently, the observed 
fluorescence is proportional to the insertion of leucine at that specific position 
(Figure 16) (20).  
 
 
 
Figure 15 - Experimental evolution of 9 clones of each strain T0, T1 and T2 with 
fluconazole. Cultures were grown at 37ºC in RPMI media. The MIC values were determined 
using the European Committee on Antimicrobial Susceptibility Testing (EUCAST protocol) and 
revealed the lowest fluconazole concentration giving rise to an inhibition of growth of ±50%. The 
MIC values for strain T0 revealed that 2 clones reached the MIC~256µg/ml (A), the MIC values for 
strain T1 revealed that 2 clones reached the MIC~256µg/ml (B) and the MIC values for strain T2 
revealed that 5 clones reached the MIC~256µg/ml (C). 
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In our study, we used nine clones of each of the ambiguous strains T0, T1 and 
T2 where increased levels of incorporation of Leu were generated by inserting a 
copy (T1) or two copies (T2) of a mutant tRNALeuCAG gene. Among the nine 
clones of each strain (T0, T1 and T2), three function as positive controls 
(containing the UUA-Leu codon at position 201 of the yEGFP gene), three were 
negative controls (containing the UCU-Ser codon at position 201 of the yEGFP 
gene) and the other three were reporter clones (containing the CUG codon at 
position 201) (Figure 17). 
 
 
 
 
Figure 16 - Fluorescent reporter system to quantify leucine insertion at CUG positions in vivo. The 
system was based on the yeast-enhanced green fluorescent protein (yEGFP) gene. The leucine UUA 
codon at position 201 was mutated to the ambiguous CUG codon and to a UCU serine codon. Cell 
fluorescence was determined using a microscope and images were processed using ImageJ software. The 
level of fluorescence was directly proportional to the amount of leucine incorporated at the CUG-201 
(Adapted from reference 20). 
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Clones carrying the different versions of the reporter were grown overnight in 
liquid media and fluorescence was measured by epifluorescence microscopy at 
the beginning of the evolution, in the breakpoint passage and in the final stage 
of the experiment. Photographs were taken and absolute GFP fluorescence 
intensities were quantified for individual yeast cells using ImageJ software. In 
each case, mean fluorescence intensities (± standard deviation) were 
calculated for at least 1000 individual cells. After obtaining the values of 
intensity of fluorescence of clones UUA201 (positive control) and Ser/Leu-
Figure 17 – Strains of C. albicans used in experimental evolution of resistance to fluconazole.  Three 
strains (T0, T1 and T2) were tested and each strain had 9 different clones. Among the 9 clones evolved, 
there were 3 positive controls (UUA201 codon), 3 negative controls (UCU201 codon) and 3 reporter clones 
(CUG201 codon). 
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CUG201 (reporter), the value of fluorescence of the clones Ser-UCU201 (negative 
control) was subtracted and the ambiguity level was obtained as a ratio 
between CUG201 and UUA201 (Figure 18). All the others absolute values of 
fluorescence for each version of the reporter system and final calculation of the 
percentage of mistranslation are in the section annexes (Figure 25-34 in 
annex). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 – Example of absolute values of fluorescence for each version of the reporter system and final 
calculation of the percentage of mistranslation of the strain T0 at the passage 5 of evolution without 
fluconazole (B). Absolute values of each clone (A). 
A. 
B. 
 
45 
 
 
 
As exemplified in Figure 18, it was possible to obtain the percentage of 
mistranslation in each strain at different stages of the evolution experiment with 
and without fluconazole (Figure 19, 20 and 21).  
 
Results show that the values of mistranslation in strain T0 over the entire 
evolution experiment remain similar. Also, results are identical to the clones that 
grow with drug and without drug (Figure 19). In the beginning of evolution, T0 
strain had ~1.5% of ambiguity and this value was maintained in passage 5. In 
the end of the evolution, strain T0 showed 0.1% of leucine misincorporation in 
both cases, with and without drug (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
A different trend was observed for the strain T1 (Figure 20). In this case, in the 
beginning of evolution T1 strain had ~20% of ambiguity and this value was 
maintained in passage 5 and 10 of the evolution with fluconazole. In the 
Figure 19 – Percentage of mistranslation of strain T0 in passages 0, 5 and 10. In media without 
drug, the percentage of mistranslation ranges from 1.45 ± 0.6%, 1.46 ± 1.1 % and 0.1 ± 1.1 %, referent 
to passage 0, 5 and 10, respectively. In media with drug, the percentage of mistranslation ranges from 
1.45± 0.6%, 1.67± 1.3% and 0,1± 1%, referent to passage 0, 5 and 10, respectively. The statistical test, t-
test, demonstrated that there is no statistical significance. 
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evolution without drug, levels of leucine misincorporation were slightly increased 
in passage5 and 10 (~30%). Although there was this notorious increase, this 
result was not statistically significant (Figure 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the case of strain T2, it was observed a clear decrease in the ambiguity level 
over the evolution process with and without drug (Figure 21). In the beginning of 
evolution, T2 strain had ~67% of ambiguity and this value drastically decreased 
in passage 5 (5.27% without drug and 18.76% with drug). This is likely due to a 
deletion of a fragment or part of the second copy of the tRNACAG
Leu gene 
inserted at the RPS10 locus (results in section 2.1 below) in all clones of the 
strain T2. At passage 10, it was not possible to quantify the level of leucine 
misincorporation in both media with and without drug. The presence of cellular 
aggregates and the high level of auto-fluorescence of the cells that grew in 
media with drug, made it impossible to quantify the fluorescence (Figure 21). 
 
 
Figure 20 - Percentage of mistranslation of strain T1 in passage 0, 5 and 10. In media without 
drug, the percentage of mistranslation ranges from 20.61± 1.8%, 29.56± 9% and 29.02± 10%, referent 
to passage 0, 5 and 10, respectively. In media with drug, the percentage of mistranslation ranges from 
20.61± 1.8%, 18.88± 9% and 21.05± 12%, referent to passage 0, 5 and 10, respectively. The statistical 
test, t-test, demonstrated that there no statistical significance. 
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2.1. Sequencing of the insertion at RP10 locus  
 
As mentioned above, strain T2 showed a sharp decrease in mistranslation, as 
soon as passage 5, in both evolutions with and without drug. This decrease 
rendered a value similar to that of T1 strain (~20%), which prompted us to 
confirm that there was not cross-contamination of the more resistant strain T2 
with a less resistant strain. In order to do that, we analyzed a fragment of the 
RPS10 locus of all clones to confirm the presence of the two insertions of the 
tRNACAG
Leu gene (T2). If there is one insertion of tRNACAG
Leu gene, clones 
belonged to strain T1 and if there was no insertion of the tRNACAG
Leu gene, 
clones belonged to strain T0. 
 
A portion of the RPS10 locus of all evolved clones was amplified from genomic 
DNA using standard PCR techniques. The amplified fragment was purified and 
Figure 21 - Percentage of mistranslation of strain T2 in passages 0, 5 and 10. In media without 
drug, the percentage of mistranslation ranges from 67.29± 6.8% to 5.27± 7%, referent to passage 0 and 
5, respectively. In media with drug, the percentage of mistranslation ranges from 67.29± 6.8% to 
18.76± 11% referent to passage 0 and 5, respectively. The values for passage 10 (*) were impossible to 
quantify correctly. 
* * 
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sequenced using the services of Stavida. Results revealed a deletion of a 
fragment containing the second tRNACAG
Leu inserted on the RPS10 locus in all 
clones of the strain T2 evolved with fluconazole (Figure 22A). To confirm when 
this deletion may have occurred and if the presence of the drug was the trigger 
for the deletion, we also sequenced clones of strain T2 at passage 5 of the 
evolution without fluconazole. Results demonstrate that there was a deletion in 
clones evolved without fluconazole at passage 5 (Figure 22B). 
 
 
 
 
 
 
3. Identify molecular determinants by which resistance evolves 
in mistranslating strains 
 
The increased fluconazole resistance observed in the strains with higher level of 
mistranslation may arise from transient physiological changes or more stable 
genetic changes. To verify if the increased drug resistance was stable, clones of 
strain T2 that presented a MIC of 256 µg/ml at passage 10 were subjected to 
the consecutive transfer in fresh media without fluconazole for three passages. 
After this, MICs were again measured and compared to the MICs of the original 
Figure 22 - Result of sequencing of RPS10 locus. Sequence of three clones of the strain T2 and two of the 
strain T1 belonging to passage 10 of the evolution with fluconazole (A). Sequence of one clone of the strain 
T2 at passage 5 of the evolution without fluconazole (B). 
A. 
B. 
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mutants. Notably, MIC values of all the clones tested did not decrease following 
the nonselective serial transfer and always remained higher than the MIC 
values of the parental strain, suggesting that the drug resistance is stable for a 
period of at least three passages and is likely due to a genetic change rather 
than a phenotypic resistance. 
 
Several mechanisms of resistance to fluconazole have been described. They 
can be separated in three categories: alteration of drug target, upregulation of 
drug transporters and cellular stress responses (83, 84). One of the most studied 
mechanisms concerns the mutation of the drug target ERG11, which decreases 
the affinity of azole the binding. In fact, the three-dimensional structure of C. 
albicans Erg11 was modeled, and residues important for its interaction with the 
azoles were predicted (Figure 23) (142). At least 12 different point mutations 
clustering in 3 “hot-spots” in ERG11 gene have been associated with azole 
resistance in clinical isolates (143).  
 
 
 
 
 
 
 
 
 
 
 
 
In order to verify if there are mutations in any of those “spots” in the ERG11 
gene of our resistant evolved clones, we amplified ERG11from genomic DNA 
Figure 23 - Mapping of C. albicans mutations in azole-resistant isolates onto Erg11 structure. Red 
and yellow colors correspond to the most dynamic regions of MTCYP51. Numbering of residues in the 
figure is according to C. albicans. (Adapted from reference 132). 
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using standard PCR techniques. The amplified fragment was purified and 
sequenced using the services of Stavida. Results showed that all clones of 
strain T2 with a MIC of 256 µg/ml at passage 10 have 2 specific mutations, the 
K128T and F105L (Figure 24). These are 2 mutations that are known to cause 
azole resistance in clinical strains. Clones that were not resistant to fluconazole 
did not show these mutations. Also, a few other resistant clones had the 
mutations I471T and G464S (data not show) but these were not present in all 
clones of the T2 strain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 - Sequencing of the ERG11 gene. Sequencing of the ERG11 gene from resistant clones of strain 
T2 grown in media with fluconazole showed the K128T and F105L mutations. 
K128T  
 
F105L  
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IV. Discussion 
 
Relatively few experimental evolution projects have been performed with 
eukaryotic pathogens. Yet Candida albicans is the most prevalent fungal 
pathogen of humans and is commonly treated with fluconazole because of its 
low toxicity, low cost and oral availability. The acquisition of drug resistance is 
an evolutionary process and the prolonged use of fungistatic antifungal 
therapies increases the incidence of acquired antifungal drug resistance (79, 144). 
One series of studies by Cowen et al. tackled this challenge by following 
adaptation by the pathogenic fungus (145) Candida albicans to inhibitory 
concentrations of the antimicrobial drug fluconazole. Six independent 
populations were exposed to either steady or increasing concentrations of the 
antibiotic, depending on the level of the most recently measured minimum 
inhibitory concentration (MIC). Six additional populations were passaged in the 
absence of antibiotic; these served as controls for adaptation to the laboratory 
environment in general and not the antibiotic. As in the previous studies, each 
of these populations was founded by a single clone with no capacity for genetic 
exchange between individuals, so all variation arose de novo by mutation during 
the experiment. This stochastic variation arising uniquely within each population 
allowed the authors to study how chance affects the evolution of azole 
resistance in C. albicans (145). 
 
The evolution of drug resistance depends on phenotypic variability, and the 
ultimate source of that variability has been considered to be mutations that alter 
gene expression or protein activities (145). Recent studies indicate that copy 
number variation (CNV), including short segmental CNV and whole 
chromosome aneuploidy, are important contributors to genetic variation leading 
to drug resistance (146, 147). 
 
A previous study of Bezerra et al showed that strains with more Leu 
misincorporation (strain T2 with 67,29% ± 8,83%) grew better in media with 
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fluconazole and itraconazole (20), which suggested that  that CUG ambiguity is 
relevant to evolution of antifungal drug resistance, particularly in the case of 
azoles. In the same work was possible to show that in strain T2, genes with a 
higher number of CUGs accumulated more SNPs. The study of Bezerra and 
coworkers also showed that highly ambiguous strains had loss of 
heterozygosity, which can arise via chromosome missegregation and/or via 
recombinations events, namely in chromosome R, which contains the genes 
coding for rDNA, and in chromossome 5, which contains genes that are 
involved in the regulation of biological process, namely stress response and 
antifungal drug resistance (20, 145). This suggested that mistranslation is 
accompanied by an increased frequency of genomic changes that can interfere 
with the response to drug treatment in C. albicans. 
 
Also, Selmecki et al demonstrated in their studies that chromosomal 
rearrangements, like aneuploidy, confer drug resistance. As an example is the 
i(5L), an isochromosome composed of two identical arms (Chr5L) flanking 
centrometer (49).  TAC1 is located is located ∼48 kb from the centromere on the 
left arm of chromosome 5 (Chr 5) and it is a transcription factor that 
activates CDR1 and CDR2 expression (95, 148). ERG11 is also located at this 
chromosome, ∼150 kb from the left telomere (49). 
 
Others studies suggest that codon ambiguity leads to adaptation under stress 
conditions (increase the fitness) like in the presence of drugs and the process of 
adaptation results from the development of mechanisms such metabolic 
alterations, activations of chaperons and signaling transduction cascades, that 
also contribute to drug tolerance (84). 
 
In this experimental study, we were to check the role of tRNA mistranslation on 
the acquisition of resistance through evolution in media with and without 
fluconazole, based on the determination of MIC. The MIC of an antifungal agent 
is an important indicator of drug susceptibility (144).  
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It was observed that all strains (T0, T1 and T2), that grew in the absence of 
fluconazole, kept the sensitivity levels throughout evolution (MIC~ 0.125µg/ml) 
(Figure 14). Thus, the presence of drug is fundamental to the acquisition of 
resistance. The results of the experimental evolution with fluconazole showed 
that among the 9 clones of strain T0, two clones achieved the highest level of 
fluconazole resistance (MIC~ 256µg/ml). The same occurred with strain T1 
where two clones achieved the highest level of fluconazole resistance (MIC~ 
256µg/ml) and other clones achieved an intermediate level of resistance. 
Among the 9 clones tested of strain T2, five clones achieved the highest level of 
fluconazole resistance (MIC~ 256µg/ml). So strains with more ambiguity, T1 
and T2, obtained more resistance in relation to T0 strain, and the T2 strain 
acquires more resistance, quicker and more stable compared to the strain T1 
(Figure 15). In this study, it is also shown that passage 5 is the turning point for 
the three strains (T0, T1 and T2) in the presence of drug. After this passage, 
strains gradually acquired more resistance. 
 
During a period of drug treatment, reversible resistance often develops such 
that when selection is relaxed resistance levels can drop (91). The acquisition of 
unstable resistance has been documented in clinical isolates from patients 
treated with azole antifungals (149). In our study, MIC values of all the clones 
tested did not decrease following the nonselective serial transfer and always 
remained higher than the MIC values of the parental strain, suggesting that the 
drug resistance is stable for a period of at least three passages and is likely due 
to a genetic change rather than phenotypic resistance. 
 
The work of Lamb and Sanglard demonstrated that C. albicans drug tolerance 
involves mutations in the antifungal target gene, ERG11, which encodes for 
enzyme lanosterol 14-α demethylase. These mutations usually block drug 
binding (87, 89). Studies of Morschhãuser and de Micheli (94, 150) revealed that 
overexpression of multiple drug resistance genes such as ATP-binding cassette 
(ABC) transporters and the major facilitator superfamily (MFS) membrane 
transporters can also be responsible for removing the drug of the cell.  Other 
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studies showed that some enzymes involved in the ergosterol biosynthesis 
pathways, such as Erg3, have been associated with azole resistance in C. 
albicans clinical isolates (151, 152). In this work, we have analyzed one 
mechanism of resistance, the alteration of the target enzyme. The results 
suggest that the resistance acquired by T2 clones may be due to 2 mutations 
found in Erg11, precisely the K128T and F105L alterations (Figure 24). We 
have analysed this mechanism because several studies mentioned that at least 
12 different point mutations in ERG11 gene have been associated with azole 
resistance in clinical isolates (88, 143). In a future work it would be interesting to 
verify possible other mechanisms involved in resistance, such mutations in 
ERG3 and upregulation of multidrug transporters. 
 
Relative to the mistranslation level, it appears that throughout evolution with and 
without drug, T0 and T1 strains maintained the levels of ambiguity identical to 
the original values. The results showed that the values of mistranslation in strain 
T0 over the different passages were similar with a minimum of 0.1% and 
maximum of 1.67% (Figure 19). The same happened for the strain T1 over the 
evolution with a minimum of 18.49% and maximum of 29.56% (Figure 20). 
Results were identical among clones that grew with drug and without drug. In 
the case of strain T2, it was observed a clear decrease in the ambiguity level 
over the passages with a minimum of 5.27% and maximum of 67% (Figure 21). 
This occurred even without drug, suggesting that 67% of ambiguity is not within 
the physiological range tolerated by C. albicans cells. Indeed, previous studies 
showed a variation between 1.5% and 28% in ambiguity under environmental 
stress, with minimal decrease in growth rate (18). 
 
The genomic instability of high mistranslating strains may also explain the 
decrease in ambiguity level. This decrease may be due to a deletion of a 
fragment of the RPS10 locus containing the second tRNACAG
Leu (Figure 22A). 
Thus, the strain T2 that was supposed to have two insertions of the tRNACAG
Leu 
gene has only one insertion of the mutant gene. Therefore, strain T2 acquired a 
typical behavior of strain T1, hence the decrease of mistranslation. In addition, it 
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was possible to verify that this deletion had already occurred at the turning point 
of the evolution, the passage 5. Results demonstrated the appearance of the 
deletion in both evolution experiments, with and without fluconazole (Figure 
22B). So, this deletion does not depend of the presence of drug, but it is rather 
due to the evolution process itself.  
 
With this experimental work it was possible to verify that genetic code ambiguity 
may provide an initial step for the acquisition of resistance but then becomes 
intolerable, which in turn results in the decrease of ambiguity levels. 
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V. Conclusions and future 
perspectives 
 
Genetic code ambiguity and the pressure exerted by the presence of the drug 
deliver a powerful mechanism to induce resistance. Our data suggest that the 
acquisition of resistance is dependent on the drug and the percentage of 
mistranslation. Results also demonstrated that strains with increased 
mistranslation (T2) acquired more resistance and faster than the 
control. Mutations in ERG11 gene might be part of the mechanism of 
resistance. Also, T2 strain showed a decrease in mistranslation level during 
both evolution experiments (with and without drug) as a consequence of the 
deletion of one of the two copies of the mutant tRNACAG
Leu gene. This further 
highlights the genetic instability of strain T2. It will be interesting to identify more 
molecular determinants involved in the acquisition of resistance, namely the 
increased expression of pumps genes and mutations in ERG 3 gene, as well as 
sequencing of the whole genome of each clone. 
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VII. Annexes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 - Percentage of mistranlation of the strain T0 of the 5 passage grew without 
fluconazole (B). Absolut values of each clone (A). 
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Figure 26 - Percentage of mistranlation of the strain T1 of the 5 passage grew without 
fluconazole (B). Absolut values of each clone (A). 
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A. 
Figure 27 - Percentage of mistranlation of the strain T2 of the 5 passage grew without 
fluconazole (B). Absolut values of each clone (A). 
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Figure 28 - Percentage of mistranlation of the strain T0  of the 5 passage grew with 
fluconazole (B). Absolut values of each clone (A). 
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A. 
Figure 29 - Percentage of mistranlation of the strain T1 of the 5 passage grew with 
fluconazole (B). Absolut values of each clone (A). 
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Figure 30 - Percentage of mistranlation of the strain T2 of the 5 passage grew with 
fluconazole (B). Absolut values of each clone (A). 
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B. 
Figure 31 - Percentage of mistranlation of the strain T0 of the 10 passage grew without 
fluconazole (B). Absolut values of each clone (A). 
B. 
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A. 
B. 
Figure 32 - Percentage of mistranlation of the strain T1 of the 10 passage grew without 
fluconazole (B). Absolut values of each clone (A). 
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Figure 33 - Percentage of mistranlation of the strain T0 of the 10 passage grew with 
fluconazole (B). Absolut values of each clone (A). 
B. 
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B. 
A. 
Figure 34 - Percentage of mistranlation of the strain T1 of the 10 passage grew with 
fluconazole (B). Absolut values of each clone (A). 
